Torsdag 9 Juli | 01:29:31 Europe / Stockholm
Svenska | English
Est. tid*
2027-03-03 N/A Bokslutskommuniké 2026
2026-08-20 07:30 Kvartalsrapport 2026-Q2
2026-04-07 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2026-03-26 - Årsstämma
2026-02-27 - Bokslutskommuniké 2025
2025-08-21 - Kvartalsrapport 2025-Q2
2025-06-30 - X-dag bonusutdelning GUBRA 61.2
2025-06-27 - Extra Bolagsstämma 2025
2025-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2025-04-03 - Årsstämma
2025-02-28 - Bokslutskommuniké 2024
2024-08-23 - Kvartalsrapport 2024-Q2
2024-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-01 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2
LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Major shareholder announcement: The Capital Group Companies, Inc.

2026-07-08 20:00:00

With reference to Section 30 of the Danish Capital Markets Act, Gubra has received notifications from The Capital Group Companies on July 6, 2026, regarding changes to its shareholding and voting rights position in Gubra. Following these notifications, The Capital Group Companies holds less than 5% of the share capital and voting rights in Gubra.

The notifications were made by The Capital Group Companies, Inc. on behalf of affiliated investment management entities and funds under management. The reported holding relates to shares legally held by SMALLCAP World Fund, Inc., for which Capital Research and Management Company has been granted proxy voting authority.

Contacts at Gubra
Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Adam Lange (adl@gubra.dk, +45 6646 1589)

About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025. See www.gubra.dk for more information.

This information is information which Gubra is obliged to make public pursuant to the Danish Capital Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-07-08 20:00 CEST.

Attachments
Major shareholder announcement: The Capital Group Companies, Inc.
Gubra AS 2026 07 02 CGC
Gubra AS 2026 07 02 SCWF

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden